Business Context and Reporting Period
The Chemours Company (NYSE: CC) filed a Current Report on Form 8-K on March 18, 2024. The filing addresses a regulatory compliance issue regarding the company's listing status on the New York Stock Exchange (NYSE).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural notice regarding listing compliance rather than a financial results report.
Material Changes
The material event reported is the receipt of a notice from the NYSE on March 18, 2024, stating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual. This noncompliance stems from the failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Outlook, Risks, and Management Commentary
- Management Action: The Company has contacted the NYSE to discuss the status of its Form 10-K filing.
- Public Disclosure: A press release regarding the notice of noncompliance was issued on March 18, 2024, and is attached as Exhibit 99.1.
- Risk: The primary risk identified is the potential for delisting or failure to satisfy continued listing standards due to the late filing of the annual report.
Investor Verification Checklist
- Verify the current status of the Form 10-K for the year ended December 31, 2023, and whether it has been filed since March 18, 2024.
- Review the attached press release (Exhibit 99.1) for specific details on the timeline for resolving the filing delay.
- Monitor subsequent communications from the NYSE regarding the Company's compliance status and potential delisting proceedings.
- Confirm the identity of the Interim Chief Financial Officer, Matthew S. Abbott, who signed the report.